Get the Stockscreener App
630.30
0.10%
0.62
Pre-market:
630.30
Regeneron Pharmaceuticals Inc stock is traded at $630.30, with a volume of 1.45M.
It is up +0.10% in the last 24 hours and down -16.02% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
See More
Previous Close:
$629.68
Open:
$630.49
24h Volume:
1.45M
Relative Volume:
1.98
Market Cap:
$66.08B
Revenue:
$14.92B
Net Income/Loss:
$4.42B
P/E Ratio:
15.36
EPS:
41.0422
Net Cash Flow:
$3.79B
1W Performance:
-12.87%
1M Performance:
-16.02%
6M Performance:
-10.31%
1Y Performance:
+5.66%
1-Day Range:
$616.02
$639.99
1-Week Range:
$610.60
$730.59
52-Week Range:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Resumed | Piper Sandler | Overweight |
| Mar-06-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy - Moomoo
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B - Yahoo Finance
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - Yahoo Finance Singapore
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price Pullback - Yahoo Finance
Regeneron Stock Tumbles 12% After Experimental Cancer Drug Misses Key Trial Goal - TIKR.com
REGN Maintained by Canaccord Genuity -- Price Target Lowered to $875 - GuruFocus
Canaccord Genuity Group Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $875.00 - MarketBeat
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $770 to $968 - Moomoo
REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations - PR Newswire
Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal - Yahoo Finance
Canaccord lowers Regeneron stock price target on pipeline concerns By Investing.com - Investing.com Canada
Regeneron teams up with Parabilis to advance novel antibody Helicon - The Pharma Letter
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates - Pharmaceutical Technology
North Dakota State Investment Board Acquires Shares of 3,579 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc stock (US7739031091): strategic Parabilis deal after REGN sell-off - AD HOC NEWS
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Handelsbanken Fonder AB - MarketBeat
Regeneron Melanoma Setback And New Collaboration Reshape Oncology Outlook - simplywall.st
Could Cash Machine Regeneron Pharmaceuticals Stock Be Your Next Buy? - Trefis
Between Incyte and Regeneron Pharmaceuticals, Which Stock Looks Set to Break Out? - Trefis
Wolfe Research lowers Regeneron stock price target to $860 on LAG-3 miss By Investing.com - Investing.com Australia
Regeneron stock sinks after cancer trial miss prompts selloff - TechStock²
Regeneron Pharma Update Signals New Market Watchpoint - Kalkine Media
Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN) - PR Newswire
Regeneron Partners With Parabilis To Reach Undruggable Targets - Citeline News & Insights
Wolfe Research lowers Regeneron stock price target to $860 on LAG-3 miss - Investing.com Nigeria
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda - Barron's
Investigation launched into Regeneron over misleading trial optimism and stock drop - Pluang
U.S. Indexes Finished Mixed Monday As Cognizant Tech Solutions Led, Regeneron Pharmaceuticals Lagged - Barron's
Wolfe Research Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $860 - Moomoo
Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock. - Barchart.com
Why Regeneron (REGN) Shares Are Trading Lower Today - The Globe and Mail
Regeneron stock drops double digits on oncology trial failure - TradingView
REGN Downgraded by Citigroup -- Price Target Lowered to $700 - GuruFocus
REGN Maintained by Truist Securities -- Price Target Lowered to $778 - GuruFocus
Regeneron's Late-Stage Melanoma Study Misses Primary Goal - Yahoo Finance
Leerink cuts Regeneron stock rating on melanoma drug failure By Investing.com - Investing.com Australia
REGN Maintained by BMO Capital -- Price Target Lowered to $730 - GuruFocus
BMO Capital Markets Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $730.00 - MarketBeat
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 10.44% on May 18: Facts Behind the Movement - TradingKey
Nvidia Earnings Could Decide Whether the AI Trade Still Holds - Investing.com
Cantor Fitzgerald cuts Regeneron stock price target to $785 on trial failure - Investing.com UK
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down After Analyst Downgrade - MarketBeat
Regeneron Pharmaceuticals (REGN) Faces Setback in Melanoma Trial Results - GuruFocus
Regeneron Faces Nasdaq Composite Heat After Downgrade - Kalkine Media
Truist Financial Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
REGN Maintained by RBC Capital -- Price Target Lowered to $707 - GuruFocus
Regeneron: Time To Forget Fianlimab (Rating Upgrade) (NASDAQ:REGN) - Seeking Alpha
Regeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis - BioWorld News
REGN Maintained by JP Morgan -- Price Target Lowered to $850 - GuruFocus
Regeneron Pharmaceuticals Trial Miss May Raise Broader Strategy Questions, RBC Says - Moomoo
Micron, Regeneron, UnitedHealth, Dominion Energy, Ford, Tesla, Lumentum, and More Movers - Barron's
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):